Cannabosides Show Positive Results as Potential Colitis Treatment in Preclinical Studies

Cannabosides Show Positive Results as Potential Colitis Treatment in Preclinical Studies
A new class of ingestible cannabinoid prodrugs known as cannabosides developed to treat colitis have shown positive results in preclinical studies, Vitality Biopharma has announced. Cannabosides are a modification of a novel class of chemical compounds called cannabinoids found in the cannabis plant. By ingesting cannabosides, their action is targeted and limited to the gastrointestinal tract. Other body locations are shielded from the compound's action, limiting unforeseen side effects. In preclinical studies with a model for inflammatory bowel disease (IBD), researchers observed that cannabosides reduced weight loss and decreased damage to the colon (large intestine). These eff
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *